Институт стволовых клеток человека ISKJ

Институт стволовых клеток человека Balance Sheet 2006-2026 | ISKJ

Annual Balance Sheet Институт стволовых клеток человека

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Cash And Cash Equivalents	545 M	202 M	193 M	107 M	89.7 M	64.4 M	107 M	286 M	50.8 M	70.8 M	18.1 M	26.7 M	17.4 M	70 M	155 M	4.32 M	5.33 M	1.63 M
Total Current Assets	1.12 B	690 M	658 M	576 M	510 M	474 M	393 M	562 M	361 M	327 M	216 M	166 M	104 M	147 M	186 M	19.7 M	23.1 M	12.8 M
Property Plant Equipment Net	316 M	281 M	285 M	330 M	379 M	277 M	283 M	153 M	96.6 M	110 M	117 M	66.2 M	37 M	35.8 M	33.4 M	26.2 M	10.5 M	3.74 M
Intangible Assets	175 M	737 M	543 M	459 M	420 M	316 M	108 M	59.2 M	47.7 M	50.6 M	36.9 M	48.5 M	-	-	-	-	-	-
Goodwill And Intangible Assets	175 M	737 M	543 M	459 M	420 M	316 M	108 M	59.2 M	47.7 M	50.6 M	36.9 M	49.5 M	28.9 M	2.88 M	1.54 M	1.36 M	108 K	115 K
Long-Term Investments	161 M	112 M	95.5 M	34.5 M	-82.2 M	-	223 M	155 M	155 M	178 M	264 M	-	-	-	-	-	-	-
Tax Assets	-	83 M	86.1 M	76 M	65 M	57.4 M	22.8 M	17.8 M	13.1 M	3.26 M	2.33 M	1.6 M	6.52 M	2.14 M	260 K	245 K	276 K	48 K
Total Non Current Assets	1.43 B	1.35 B	1.08 B	936 M	889 M	651 M	660 M	477 M	471 M	479 M	513 M	837 M	877 M	148 M	86.4 M	45.6 M	13.9 M	6.92 M
Total Assets	2.54 B	2.04 B	1.74 B	1.51 B	1.4 B	1.12 B	1.05 B	1.04 B	833 M	806 M	729 M	1 B	981 M	295 M	273 M	65.3 M	37 M	19.7 M
Account Payables	53.4 M	66.8 M	102 M	97.4 M	82.6 M	122 M	72.8 M	87.6 M	19.3 M	9.3 M	16.2 M	15 M	27.2 M	6.22 M	11 M	42.8 M	21.9 M	13.3 M
Short-Term Debt	240 M	119 M	9.09 M	188 M	146 M	51.9 M	51 M	38.9 M	90 M	98.9 M	91.9 M	88.9 M	9.71 M	15 K	8 K	3.02 M	-	-
Tax Payables	-	24.6 M	14.6 M	10.7 M	4.88 M	9.01 M	6.33 M	4.28 M	2.4 M	2.07 M	6.97 M	3.43 M	4.8 M	940 K	2.85 M	2.25 M	1.15 M	186 K
Deferred Revenue	-	-	14.6 M	10.7 M	4.88 M	9.01 M	6.33 M	4.28 M	2.4 M	2.07 M	6.97 M	-	-	-	-	-	-	-
Total Current Liabilities	561 M	396 M	372 M	556 M	487 M	413 M	558 M	477 M	419 M	365 M	326 M	203 M	102 M	99.8 M	77.2 M	48.1 M	23 M	13.5 M
Long-Term Debt	547 M	713 M	608 M	301 M	278 M	323 M	363 M	307 M	24.6 M	-	37.1 M	63.1 M	739 K	-	-	-	-	-
Deferred Revenue Non Current	-	-	-	-	263 M	265 M	-	-	-	-	-	3.9 M	1.73 M	664 K	4 K	-	-	-
Deferred Tax Liabilities Non Current	-	-	-	-	318 K	2.52 M	3.51 M	15.7 M	29.7 M	18.6 M	3.18 M	3.9 M	94.4 M	-	-	-	1 K	2 K
Total Non Current Liabilities	1.01 B	1.08 B	905 M	541 M	541 M	590 M	367 M	323 M	54.4 M	18.6 M	40.2 M	129 M	61.6 M	664 K	4 K	45.8 M	1 K	2 K
Total Liabilities	1.57 B	1.47 B	1.28 B	1.1 B	1.03 B	1 B	925 M	801 M	473 M	384 M	367 M	333 M	163 M	100 M	77.2 M	48.1 M	23 M	13.5 M
Retained Earnings	318 M	146 M	94.1 M	69.4 M	-9.97 M	-94.5 M	-53.3 M	71.8 M	183 M	235 M	248 M	550 M	74.4 M	44.4 M	45.5 M	9.8 M	6.42 M	259 K
Accumulated Other Comprehensive Income Loss	-30.1 M	-	-	-	-	-178 M	-135 M	-101 M	-82.6 M	-62.9 M	-44.9 M	-24 M	-17.5 M	-11.6 M	-6.6 M	-3.04 M	-814 K	-
Total Stockholders Equity	500 M	341 M	235 M	194 M	98.7 M	27 M	51.2 M	154 M	288 M	339 M	352 M	658 M	808 M	193 M	194 M	15.8 M	12.4 M	6.26 M
Total Liabilities And Stockholders Equity	2.54 B	2.04 B	1.74 B	1.51 B	1.4 B	1.12 B	1.05 B	1.04 B	833 M	806 M	729 M	1 B	981 M	295 M	273 M	65.3 M	37 M	19.7 M
Total Investments	189 M	193 M	121 M	54.3 M	18.2 M	141 M	245 M	247 M	314 M	314 M	349 M	709 M	789 M	97.3 M	43 M	11.9 M	1.07 M	1.07 M
Total Debt	787 M	832 M	617 M	488 M	424 M	374 M	414 M	346 M	115 M	98.9 M	129 M	149 M	10.5 M	15 K	8 K	3.02 M	-	-
Net Debt	242 M	630 M	424 M	381 M	334 M	310 M	307 M	60.7 M	63.9 M	28 M	111 M	122 M	-6.91 M	-70 M	-154 M	-1.3 M	-5.33 M	-1.63 M

All numbers in RUB currency

Quarterly Balance Sheet Институт стволовых клеток человека

	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q3
Cash And Cash Equivalents	370 M	370 M	545 M	545 M	362 M	362 M	202 M	202 M	59.4 M	59.4 M	193 M	193 M	48.5 M	48.5 M	107 M	107 M	158 M	158 M	89.7 M	89.7 M	58.7 M	58.7 M	64.4 M	64.4 M	78.7 M	78.7 M	107 M	108 M	182 M	333 M	286 M	282 M	22.3 M	28.6 M	50.8 M	50.8 M	58.2 M	58.2 M	70.8 M	70.8 M	92.6 M	48.3 M	18.1 M	5.76 M	34 M	4.34 M	21.2 M
Total Current Assets	1.02 B	1.02 B	1.12 B	1.12 B	951 M	951 M	690 M	690 M	583 M	583 M	658 M	658 M	531 M	531 M	576 M	576 M	650 M	650 M	510 M	510 M	502 M	502 M	474 M	474 M	470 M	470 M	393 M	428 M	469 M	634 M	562 M	518 M	293 M	290 M	361 M	361 M	345 M	345 M	327 M	327 M	315 M	289 M	216 M	221 M	160 M	231 M	214 M
Property Plant Equipment Net	369 M	369 M	316 M	316 M	302 M	302 M	281 M	281 M	273 M	273 M	285 M	285 M	306 M	306 M	330 M	330 M	356 M	356 M	379 M	379 M	397 M	397 M	277 M	277 M	269 M	269 M	283 M	282 M	283 M	158 M	153 M	90.4 M	93.4 M	91.3 M	96.6 M	96.6 M	100 M	100 M	110 M	110 M	82.5 M	106 M	117 M	103 M	111 M	98.4 M	38.3 M
Intangible Assets	166 M	166 M	175 M	175 M	744 M	159 M	737 M	150 M	578 M	125 M	543 M	129 M	491 M	117 M	459 M	117 M	452 M	121 M	420 M	127 M	474 M	156 M	316 M	133 M	352 M	232 M	108 M	73.5 M	68 M	58.6 M	59.2 M	23 M	48.5 M	-	47.7 M	14.8 M	51.2 M	21.2 M	21.6 M	21.6 M	43.9 M	-	16.4 M	-	93.2 M	-	-
Goodwill And Intangible Assets	166 M	166 M	175 M	175 M	744 M	159 M	737 M	150 M	578 M	125 M	543 M	129 M	491 M	117 M	459 M	117 M	452 M	121 M	420 M	127 M	474 M	156 M	316 M	133 M	352 M	232 M	108 M	73.5 M	68 M	58.6 M	59.2 M	23 M	48.5 M	46.4 M	47.7 M	14.8 M	51.2 M	21.2 M	21.6 M	21.6 M	43.9 M	6.39 M	16.4 M	17.2 M	94.2 M	23.9 M	20.5 M
Long-Term Investments	161 M	161 M	161 M	161 M	208 M	213 M	112 M	193 M	105 M	167 M	121 M	121 M	73 M	73.5 M	34.5 M	54.3 M	-6.94 M	31.8 M	-82.2 M	18.2 M	-110 M	15.2 M	-	3 K	-153 M	-	223 M	153 M	162 M	245 M	155 M	314 M	200 M	23.9 M	155 M	314 M	197 M	343 M	314 M	314 M	217 M	650 M	349 M	688 M	-	645 M	634 M
Tax Assets	-	-	-	-	89 M	-	83 M	-	87.1 M	-	86.1 M	-	81.1 M	-	76 M	-	76.5 M	-	65 M	-	37.1 M	-	57.4 M	-	30.5 M	-	22.8 M	14.4 M	13.6 M	-	17.8 M	-	5.02 M	290 M	13.1 M	-	3.58 M	-	-	-	2.98 M	1.68 M	-	4 K	1.51 M	350 K	-
Total Non Current Assets	1.49 B	1.49 B	1.43 B	1.43 B	1.4 B	1.4 B	1.35 B	1.35 B	1.17 B	1.17 B	1.08 B	1.08 B	969 M	969 M	936 M	936 M	937 M	937 M	889 M	889 M	924 M	924 M	651 M	651 M	653 M	653 M	660 M	616 M	611 M	483 M	477 M	466 M	461 M	463 M	471 M	471 M	499 M	499 M	479 M	479 M	517 M	912 M	513 M	898 M	1.01 B	851 M	747 M
Total Assets	2.51 B	2.51 B	2.54 B	2.54 B	2.36 B	2.36 B	2.04 B	2.04 B	1.75 B	1.75 B	1.74 B	1.74 B	1.5 B	1.5 B	1.51 B	1.51 B	1.59 B	1.59 B	1.4 B	1.4 B	1.43 B	1.43 B	1.12 B	1.12 B	1.12 B	1.12 B	1.05 B	1.04 B	1.08 B	1.12 B	1.04 B	984 M	754 M	818 M	833 M	833 M	844 M	844 M	806 M	806 M	832 M	1.2 B	729 M	1.12 B	1.17 B	1.08 B	961 M
Account Payables	28 M	28 M	53.4 M	53.4 M	147 M	32.8 M	66.8 M	33.9 M	111 M	54.6 M	102 M	35.9 M	89.8 M	89.8 M	97.4 M	35.4 M	104 M	32.1 M	82.6 M	41.1 M	73 M	73 M	122 M	79.9 M	85.4 M	70.9 M	72.8 M	57.1 M	100 M	83 M	87.6 M	30.7 M	52.3 M	18 M	19.3 M	15.4 M	10.7 M	5.36 M	3.97 M	3.97 M	18.4 M	247 M	6.02 M	193 M	4.71 M	182 M	-
Short-Term Debt	198 M	198 M	240 M	240 M	101 M	101 M	119 M	119 M	8.61 M	8.61 M	9.09 M	9.09 M	158 M	158 M	188 M	188 M	181 M	181 M	146 M	146 M	43.9 M	43.9 M	51.9 M	51.9 M	66.5 M	66.5 M	51 M	42.7 M	40.3 M	45.8 M	38.9 M	78.8 M	59.9 M	97.1 M	90 M	90 M	91.4 M	91.4 M	98.9 M	98.9 M	108 M	81.9 M	91.9 M	90.1 M	89 M	88.8 M	70.4 M
Tax Payables	-	-	-	-	32.1 M	-	24.6 M	-	16.8 M	-	14.6 M	-	10.2 M	-	10.7 M	-	4.69 M	-	4.88 M	-	14.2 M	-	9.01 M	-	13 M	-	6.33 M	6.74 M	6.04 M	-	4.28 M	-	3.89 M	-	2.4 M	-	3.26 M	-	-	-	5.71 M	7.14 M	-	-	4.46 M	4.84 M	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	14.6 M	-	10.2 M	-	10.7 M	-	4.69 M	-	4.88 M	-	70.8 M	-	9.01 M	-	13 M	-	6.33 M	6.74 M	6.04 M	-	4.28 M	-	3.89 M	-	2.4 M	-	3.26 M	-	-	-	5.71 M	10.5 M	-	-	-	9.28 M	-
Total Current Liabilities	540 M	540 M	561 M	561 M	455 M	455 M	396 M	396 M	294 M	294 M	372 M	372 M	403 M	403 M	556 M	556 M	460 M	460 M	487 M	487 M	411 M	411 M	413 M	413 M	585 M	585 M	558 M	458 M	496 M	499 M	477 M	406 M	419 M	416 M	419 M	419 M	362 M	362 M	365 M	365 M	336 M	340 M	326 M	283 M	152 M	280 M	240 M
Long-Term Debt	592 M	592 M	547 M	547 M	711 M	711 M	713 M	713 M	614 M	614 M	608 M	608 M	319 M	319 M	301 M	301 M	341 M	341 M	278 M	278 M	476 M	476 M	323 M	323 M	338 M	338 M	363 M	377 M	392 M	393 M	307 M	311 M	14.4 M	18.8 M	24.6 M	24.6 M	25.6 M	25.6 M	-	-	26.2 M	36 M	37.1 M	45.8 M	56.4 M	65.5 M	36.5 M
Deferred Revenue Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	263 M	-	278 M	-	265 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.5 M	-	-
Deferred Tax Liabilities Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	318 K	-	2.68 M	-	2.52 M	-	4.78 M	-	3.51 M	762 K	9.67 M	-	15.7 M	-	21.1 M	22.6 M	29.7 M	-	21.2 M	-	-	-	15.6 M	18.1 M	-	944 K	6.5 M	1.14 M	881 K
Total Non Current Liabilities	1.01 B	1.01 B	1.01 B	1.01 B	1.09 B	1.09 B	1.08 B	1.08 B	969 M	969 M	905 M	905 M	646 M	646 M	541 M	541 M	639 M	639 M	541 M	541 M	757 M	757 M	590 M	590 M	342 M	342 M	367 M	378 M	401 M	409 M	323 M	327 M	35.5 M	49.2 M	54.4 M	54.4 M	46.8 M	46.8 M	18.6 M	18.6 M	41.8 M	54.1 M	40.2 M	46.8 M	171 M	66.7 M	37.4 M
Total Liabilities	1.55 B	1.55 B	1.57 B	1.57 B	1.54 B	1.54 B	1.47 B	1.47 B	1.26 B	1.26 B	1.28 B	1.28 B	1.05 B	1.05 B	1.1 B	1.1 B	1.1 B	1.1 B	1.03 B	1.03 B	1.17 B	1.17 B	1 B	1 B	927 M	927 M	925 M	836 M	897 M	908 M	801 M	733 M	454 M	466 M	473 M	473 M	409 M	409 M	384 M	384 M	378 M	394 M	367 M	330 M	323 M	346 M	277 M
Retained Earnings	312 M	312 M	318 M	318 M	181 M	181 M	146 M	146 M	122 M	122 M	94.1 M	94.1 M	98.4 M	98.4 M	69.4 M	69.4 M	82.1 M	82.1 M	-9.97 M	-9.97 M	34.4 M	32 M	-94.5 M	-94.5 M	1.96 M	1.96 M	-53.3 M	29.8 M	5.01 M	29.4 M	71.8 M	55.6 M	120 M	-	183 M	183 M	251 M	251 M	235 M	235 M	288 M	76 M	248 M	641 M	725 M	586 M	578 M
Accumulated Other Comprehensive Income Loss	-29.4 M	-29.4 M	-30.1 M	-30.1 M	-	19.6 M	-	21.1 M	-	20 M	-	11.7 M	-	375 K	-283 M	375 K	-251 M	375 K	-221 M	375 K	-178 M	375 K	-178 M	375 K	-155 M	485 K	-135 M	-117 M	-109 M	485 K	-101 M	485 K	-90.4 M	-	-82.6 M	485 K	-73.2 M	485 K	485 K	485 K	-56.8 M	-39.6 M	-101 K	-31.2 M	-31.8 M	-24.1 M	-20.7 M
Total Stockholders Equity	433 M	433 M	500 M	500 M	381 M	381 M	341 M	341 M	276 M	276 M	235 M	235 M	223 M	223 M	194 M	194 M	216 M	216 M	98.7 M	111 M	154 M	154 M	27 M	27 M	116 M	116 M	51.2 M	134 M	110 M	134 M	154 M	160 M	202 M	280 M	288 M	288 M	356 M	356 M	339 M	339 M	447 M	808 M	352 M	790 M	833 M	735 M	684 M
Total Liabilities And Stockholders Equity	2.51 B	2.51 B	2.54 B	2.54 B	2.36 B	2.36 B	2.04 B	2.04 B	1.75 B	1.75 B	1.74 B	1.74 B	1.5 B	1.5 B	1.51 B	1.51 B	1.59 B	1.59 B	1.4 B	1.4 B	1.43 B	1.43 B	1.12 B	1.12 B	1.12 B	1.12 B	1.05 B	1.04 B	1.08 B	1.12 B	1.04 B	984 M	754 M	818 M	833 M	833 M	844 M	844 M	806 M	806 M	832 M	1.2 B	729 M	1.12 B	1.17 B	1.08 B	961 M
Total Investments	186 M	186 M	189 M	189 M	213 M	219 M	193 M	219 M	167 M	168 M	121 M	121 M	73.5 M	74 M	54.3 M	54.9 M	31.8 M	47.5 M	18.2 M	107 M	15.2 M	134 M	141 M	131 M	1.64 M	145 M	245 M	245 M	246 M	338 M	247 M	388 M	314 M	314 M	314 M	459 M	344 M	459 M	414 M	414 M	357 M	799 M	428 M	778 M	797 M	728 M	688 M
Total Debt	790 M	790 M	787 M	787 M	812 M	812 M	832 M	832 M	623 M	623 M	617 M	617 M	477 M	477 M	488 M	488 M	521 M	521 M	424 M	424 M	520 M	520 M	374 M	374 M	404 M	404 M	414 M	420 M	432 M	439 M	346 M	390 M	74.3 M	116 M	115 M	115 M	117 M	117 M	98.9 M	98.9 M	134 M	118 M	129 M	136 M	145 M	154 M	107 M
Net Debt	419 M	419 M	242 M	242 M	450 M	450 M	630 M	630 M	564 M	564 M	424 M	424 M	429 M	429 M	381 M	381 M	363 M	363 M	334 M	334 M	461 M	461 M	310 M	310 M	325 M	325 M	307 M	312 M	250 M	106 M	60.7 M	108 M	52 M	87.2 M	63.9 M	63.9 M	58.8 M	58.8 M	28 M	28 M	41.4 M	69.7 M	111 M	130 M	111 M	150 M	85.8 M

All numbers in RUB currency

Balance Sheet is a fundamental financial report of Институт стволовых клеток человека, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis

Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability.
Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer	Price	% 24h	Market Cap	Country
FSD Pharma HUGE	-	5743.5 %	$ 69.7 M	Canada
MorphoSys AG MOR	-	2.43 %	$ 254 M	Germany
Happiness Biotech Group Limited HAPP	-	1.35 %	$ 17.8 M	China
Compugen Ltd. CGEN	$ 2.22	1.37 %	$ 207 M	Israel
AgeX Therapeutics AGE	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	-	-	$ 866 M	China
Coherus BioSciences CHRS	$ 1.58	7.14 %	$ 185 M	USA
Deciphera Pharmaceuticals DCPH	-	-	$ 2.18 B	USA
Alexion Pharmaceuticals, Inc. ALXN	-	-	$ 40.3 B	USA
Genfit SA GNFT	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	-	-13.47 %	$ 169 M	France
AstraZeneca PLC AZN	-	-	$ 96.9 B	Britain
BioNTech SE BNTX	$ 89.59	1.29 %	$ 21.7 B	Germany
EyeGate Pharmaceuticals, Inc. EYEG	-	-1.52 %	$ 24.7 M	USA
Athira Pharma ATHA	-	-	$ 269 M	USA
BiondVax Pharmaceuticals Ltd. BVXV	-	0.74 %	$ 768 M	Israel
Abcam plc ABCM	-	-	$ 4.9 B	Britain
Galera Therapeutics GRTX	-	-32.59 %	$ 7.61 M	USA
Midatech Pharma plc MTP	-	-18.52 %	$ 27.3 M	Britain
Affimed N.V. AFMD	-	-34.95 %	$ 21.5 M	Germany
Checkmate Pharmaceuticals CMPI	-	-	$ 231 M	USA
Celyad Oncology SA CYAD	-	-	$ 12.5 M	Belgium
Berkeley Lights BLI	-	-7.31 %	$ 87 M	USA
Celldex Therapeutics CLDX	-	-	$ 1.99 B	USA
Generation Bio Co. GBIO	-	-	$ 344 M	USA
IMV IMV	-	-	$ 13.1 M	Canada
Akero Therapeutics AKRO	-	-	$ 3.67 B	USA
Akouos AKUS	-	0.23 %	$ 488 M	USA
Ayala Pharmaceuticals AYLA	-	-	$ 7.46 M	Israel
Cyclacel Pharmaceuticals CYCCP	-	-4.36 %	$ 27 M	USA
Freeline Therapeutics Holdings plc FRLN	-	-	$ 384 M	Britain
Gracell Biotechnologies GRCL	-	-	$ 3.37 B	China
Anika Therapeutics ANIK	$ 14.79	2.64 %	$ 212 M	USA
Advaxis ADXS	-	-9.65 %	$ 45.9 M	USA
Aeterna Zentaris AEZS	-	5.93 %	$ 314 M	Canada
Aeglea BioTherapeutics AGLE	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	-	-	$ 867 M	Germany
Applied Genetic Technologies Corporation AGTC	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-	1.93 %	$ 17.4 M	USA
Can-Fite BioPharma Ltd. CANF	-	-	$ 5.2 M	Israel
CRISPR Therapeutics AG CRSP	$ 56.95	9.35 %	$ 5.12 B	Schweiz
Aptose Biosciences APTO	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	-	-39.0 %	$ 4.57 M	USA
Albireo Pharma ALBO	-	-0.23 %	$ 916 M	USA
AlloVir ALVR	-	4.14 %	$ 49.1 M	USA
Allakos ALLK	-	-	$ 28.6 M	USA
Arcutis Biotherapeutics ARQT	$ 21.95	2.81 %	$ 2.79 B	USA
Allena Pharmaceuticals ALNA	-	3.16 %	$ 1.9 M	USA
Ampio Pharmaceuticals AMPE	-	-11.43 %	$ 502 K	USA

Институт стволовых клеток человека Balance Sheet 2006-2026 | ISKJ

Annual Balance Sheet Институт стволовых клеток человека

Cash And Cash Equivalents

Total Current Assets

Property Plant Equipment Net

Intangible Assets

Goodwill And Intangible Assets

Long-Term Investments

Tax Assets

Total Non Current Assets

Total Assets

Account Payables

Short-Term Debt

Tax Payables

Deferred Revenue

Total Current Liabilities

Long-Term Debt

Deferred Revenue Non Current

Deferred Tax Liabilities Non Current

Total Non Current Liabilities

Total Liabilities

Retained Earnings

Accumulated Other Comprehensive Income Loss

Total Stockholders Equity

Total Liabilities And Stockholders Equity

Total Investments

Total Debt

Net Debt